Cynosure Group’s Moderna MRNA Stock Holding History

Cynosure Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,836	Closed	-$496K	–	368
2025 Q4	$496K	Buy	+16,836	New	+$457K	0.05%	184

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cynosure Group's MRNA Position: Q1 2026 in Review

Cynosure Group sold out of Moderna (MRNA) in Q1 2026, closing a stake of 16,836 shares — an estimated $496K sold.

Cynosure Group first reported a position in MRNA in Q4 2025 and held it in 1 quarter. The position peaked at $496K in Q4 2025. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Cynosure Group reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
Cynosure Group sold 16,836 Moderna shares in Q1 2026, an estimated $496K.
Cynosure Group first reported a position in Moderna in Q4 2025 and held it in 1 quarter.
Cynosure Group's Moderna position peaked at $496K in Q4 2025.
723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Cynosure Group's 13F filing for Q1 2026, filed 14 May 2026.